hematological – Communicable Diseases Research

Characterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patients

Article

Published on 2022-10-012022-11-15
Journal: Cancer Medicine
[Category] COVID19(2023년), SARS, 바이오마커,

Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections

Article

Published on 2022-09-282022-11-15
Journal: Current Oncology
[Category] SARS, 변종, 진단,

[키워드] Anti-spike antibody Antigen approved average AZD1222 binding antibody BNT162b2 Breakthrough infection breakthrough infections Canada Cancer cancer patient Cancer patients Concentration contagious COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine defined demonstrated dose dosed effective Effectiveness enrolled evaluate evaluated first dose hematological highest Humoral response IgG antibody Immunity immunization immunoassay indicate Infection knowledge Level MOST mRNA-1273 no difference Observed oncology participant Patient PCR polymerase chain producing prospective cohort study Protein quantified required robust antibody response robust antibody responses SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody response SARS-CoV-2 vaccination SARS-CoV-2 variants second dose Seroconversion serological response serum solid cancer spike receptor-binding domain the mean the SARS-CoV-2 vaccination Vaccine vaccine.
[DOI] 10.3390/curroncol29100554 PMC 바로가기

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Article

Published on 2022-09-282022-11-15
Journal: Frontiers in Immunology
[Category] SARS, 변종, 진단,

[키워드] activation pathway acute kidney Acute kidney injury affecting allergies Anemia Atypical Atypical hemolytic uremic syndrome Bacterial infections bleeding Case report cause caused CD46 CFH complement complementary disease disorder dysregulation eculizumab effective Factor Factors Genetic genetic risk Haplotype hematological immune-mediated diseases Ischemia life-threatening manifested Mild monoclonal antibody mRNA vaccination mRNA vaccine mRNA vaccine against SARS-CoV-2 Mutation occurred organs pathogenic variant Patient plasma Pregnancy Protein rare disease Ravulizumab renal risk risk factor SARS-CoV-2 scleral the disease the patient thrombotic thrombotic microangiopathies. treated Treatment triggered uremic uremic syndrome vaccination
[DOI] 10.3389/fimmu.2022.1001366 PMC 바로가기

Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major

Research

Published on 2022-08-242022-10-05
Journal: Bone marrow transplantation
[Category] 바이오마커,

AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial

Clinical Trial

Published on 2022-08-162022-10-04
Journal: Frontiers in Public Health
[Category] SARS, 임상, 진단,

[키워드] Analysis Anu AYURAKSHA kit Ayurveda Blood blood sugar C-reactive protein CD3 CD4 CD8 clinical control group controls COVID-19 COVID-19 crisis COVID-19 infection COVID-19 pandemic determine distribution dysregulated effective Efficacy effort erythrocyte sedimentation rate evaluated hematological hematological parameter hematological parameters IgG IgG positivity IL-6 IL-6 level Immunity incidence India Infection inflammation marker Intervention life lower risk Lymphocyte subset management Medicine Mortality no increase non-randomized pandemic participant Participants post-intervention Primary outcome Prophylactic Quality Quality of life quality of life (QOL). random reduced reducing Research secondary outcome severity of COVID-19 significantly significantly lower status the WHO Trial Version
[DOI] 10.3389/fpubh.2022.920126 PMC 바로가기 [Article Type] Clinical Trial

Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients

혈액학적 환자에서 anti-SARS-CoV-2 mRNA 백신접종에 대한 혈청학적 반응 평가

Article

Published on 2022-08-082022-09-12
Journal: Frontiers in Immunology
[Category] SARS, 진단,

[키워드] Administered anti-SARS-CoV-2 anti-SARS-CoV-2 IgG anti-SARS-CoV-2 vaccination Anti-spike anti-Spike IgG anti-spike IgG level antibody Antibody titer association Cell Cohort cohort of patient Concentration control arm control group Cutoff demographic variable difference drug Effect evaluated greater health worker healthy healthy subjects hematological Hematological malignancies Hematological malignancy heterogeneous highest identify IgG IgG titer immune system immunoassay Immunocompromised patients Immunosuppression implication inhibitor Italy leukemia Microparticle molecular mRNA mRNA vaccination mRNA vaccine onco-hematology. parameter pathology Patient patients performed Predictive reached reduced reported SARS-CoV-2 SARS-CoV-2 antibody second dose seroconversion rate serological response shown significantly lower spike IgG statistical significance steroid stratified Surveillance the mean the patient Therapies therapy treated tyrosine underlying disease vaccination Vaccine was reduced
[DOI] 10.3389/fimmu.2022.892331 PMC 바로가기 [Article Type] Article

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases

혈액 질환 환자에서 코로나19 백신 접종 후 항체 음성 반응과 관련된 요인 정의

Article

Published on 2022-08-012022-09-12
Journal: Annals of Hematology
[Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] active treatment addition age Analysis antibody Antibody Response AstraZeneca BNT162b2 BTK inhibitor CML Combination Concentration correlated COVID-19 COVID-19 vaccination Definition demonstrated disease Efficacy Factor had no hematological Hematological diseases/disorders high mortality knowledge leukemia lymphoid median age Moderna mRNA-1273 naïve negative antibody response neoplasm Neoplasms not correlated other disease other diseases Patient patient cohort positive positive response reduced response to vaccination ruxolitinib SARS-CoV-2 seroconversion. significantly single-center study Spike protein Surveillance the SARS-CoV-2 therapy treated Treatment vaccination was performed were measured women
[DOI] 10.1007/s00277-022-04866-z PMC 바로가기 [Article Type] Article

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study

혈액 질환에서 mRNA COVID-19 백신의 체액 반응: HEMVACO 연구

Article

Published on 2022-08-012022-09-12
Journal: Infectious diseases now
[Category] COVID19(2023년), MERS, SARS, 진단,

Hematological abnormalities in immunosuppressed patients with COVID-19: Evidence from a single center. A cross sectional study

Research article

Published on 2022-08-012022-10-05
Journal: International immunopharmacology
[Category] 바이오마커,

[키워드] abnormality age baseline Blood blood cell count blood tests can be used Cell change Characteristics Complete complete blood count Concentration controls corpuscular corpuscular hemoglobin corticoid COVID-19 cross cross-sectional distribution enrolled feature finding General population hematological hematological parameter hemoglobin Immunosuppressed immunosuppressed patient immunosuppressed patients Immunosuppression individual leucocytes lymphocyte Lymphocytes management MLR neutrophil NLR Patient patients patients with COVID-19 Perspective Platelets PLR Prevalence proportion Rapid red blood cells reduced reduction Result Sex significantly significantly higher single center the disease the median therapy Volume White blood cells with COVID-19
[DOI] 10.1016/j.intimp.2022.108862 [Article Type] Research article

Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients

혈액암 환자에서 항SARS-CoV-2 백신 접종의 면역원성과 임상 효능: 365명의 환자를 대상으로 한 전향적 코호트 연구 결과

Article

Published on 2022-08-012022-09-12
Journal: American journal of hematology
[Category] MERS, 진단,

[키워드] anti-SARS-CoV-2 vaccination Clinical efficacy hematological immunogenicity Patient prospective cohort study Result
[DOI] 10.1002/ajh.26629 PMC 바로가기 [Article Type] Article